{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:20:18Z","timestamp":1793319618302,"version":"4.5.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T00:00:00Z","timestamp":1780790400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca plc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018887","name":"Roche Netherlands BV","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018887","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014369","name":"MSD Oss","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014369","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014476","name":"Pfizer BV","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014476","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.tranon.2026.102854","type":"journal-article","created":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T07:16:37Z","timestamp":1781334997000},"page":"102854","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Real-world evidence of RET fusion prevalence and testing in patients with metastatic non-small cell lung cancer"],"prefix":"10.1016","volume":"70","author":[{"given":"B.N. Cajiao","family":"Garcia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3539-8809","authenticated-orcid":false,"given":"V.D.","family":"de Jager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6533-5376","authenticated-orcid":false,"given":"C.C.H.J.","family":"Epskamp-Kuijpers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7175-0026","authenticated-orcid":false,"given":"A.J.","family":"van der Wekken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.M.","family":"Willems","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0646-0705","authenticated-orcid":false,"given":"L.C.","family":"van Kempen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3655-143X","authenticated-orcid":false,"given":"E.","family":"Schuuring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tranon.2026.102854_bib0001","first-page":"7","article-title":"Cancer statistics","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.tranon.2026.102854_bib0002","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.tranon.2026.102854_bib0003","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S0140-6736(17)33326-3","article-title":"Global surveillance of trends in cancer survival 2000\u201314 (CONCORD-3): analysis of individual records for 37\u2008513\u2008025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries","volume":"391","author":"Allemani","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.tranon.2026.102854_bib0004","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1136\/thx.2004.032698","article-title":"Symptoms and the early diagnosis of lung cancer","volume":"60","author":"Birring","year":"2005","journal-title":"Thorax"},{"key":"10.1016\/j.tranon.2026.102854_bib0005","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.ccm.2011.08.005","article-title":"Pathology of lung cancer","volume":"32","author":"Travis","year":"2011","journal-title":"Clin. Chest Med."},{"key":"10.1016\/j.tranon.2026.102854_bib0006","doi-asserted-by":"crossref","first-page":"217","DOI":"10.5306\/wjco.v12.i4.217","article-title":"Oncogenic driver mutations in non-small cell lung cancer: past, present and future","volume":"12","author":"Chevallier","year":"2021","journal-title":"World J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2026.102854_bib0007","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232315056","article-title":"Non-small cell lung cancer targeted therapy: drugs and mechanisms of drug resistance","volume":"23","author":"Wu","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.tranon.2026.102854_bib0008","article-title":"Future perspective for the application of predictive biomarker testing in advanced stage non-small cell lung cancer","volume":"38","author":"de Jager","year":"2024","journal-title":"Lancet Reg. Health - Eur."},{"key":"10.1016\/j.tranon.2026.102854_bib0009","article-title":"Developments in predictive biomarker testing and targeted therapy in advanced stage non-small cell lung cancer and their application across European countries","volume":"38","author":"De Jager","year":"2024","journal-title":"Lancet Reg. Health \u2013 Eur."},{"key":"10.1016\/j.tranon.2026.102854_bib0010","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1033484","article-title":"Targeted therapy of RET fusion-positive non-small cell lung cancer","volume":"12","author":"Shen","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.tranon.2026.102854_bib0011","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1016\/j.celrep.2017.08.037","article-title":"KIF5B-RET oncoprotein signals through a multi-kinase signaling hub","volume":"20","author":"Das","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.tranon.2026.102854_bib0012","doi-asserted-by":"crossref","first-page":"424","DOI":"10.3390\/genes11040424","article-title":"RET gene fusions in malignancies of the thyroid and other tissues","volume":"11","author":"Santoro","year":"2020","journal-title":"Genes"},{"issue":"12","key":"10.1016\/j.tranon.2026.102854_bib0013","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/nrclinonc.2017.127","article-title":"Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance","volume":"14","author":"Schram","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.tranon.2026.102854_bib0014","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1634\/theoncologist.2013-0095","article-title":"Novel targets in non-small cell lung cancer: ROS1 and RET fusions","volume":"18","author":"Gainor","year":"2013","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.tranon.2026.102854_bib0015","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/nrclinonc.2017.175","article-title":"Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes","volume":"15","author":"Drilon","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.tranon.2026.102854_bib0016","doi-asserted-by":"crossref","first-page":"6102","DOI":"10.1158\/1078-0432.CCR-20-1587","article-title":"Progresses toward precision medicine in RET-altered solid tumors","volume":"26","author":"Belli","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tranon.2026.102854_bib0017","first-page":"27","article-title":"Targeting RET-rearranged non-small-cell lung cancer: future prospects","volume":"10","author":"Bronte","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.tranon.2026.102854_bib0018","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13174415","article-title":"RET inhibitors in non-small-cell lung cancer","volume":"13","author":"Cascetta","year":"2021","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.tranon.2026.102854_bib0019","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/nm.2673","article-title":"Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies","volume":"18","author":"Lipson","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.tranon.2026.102854_bib0020","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.annonc.2020.11.021","article-title":"ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research","volume":"32","author":"Belli","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.tranon.2026.102854_bib0021","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.18408","article-title":"Clinicopathological characteristics of ROS1- and RET-rearranged NSCLC in caucasian patients: data from a cohort of 713 non-squamous NSCLC lacking KRAS\/EGFR\/HER2\/BRAF\/PIK3CA\/ALK alterations","volume":"8","author":"Dugay","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.tranon.2026.102854_bib0022","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jtho.2015.09.016","article-title":"Clinicopathological characteristics of RET rearranged lung cancer in European patients","volume":"11","author":"Michels","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.tranon.2026.102854_bib0023","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.jtho.2021.01.1619","article-title":"RET fluorescence in situ hybridization analysis is a sensitive but highly unspecific screening method for RET fusions in lung cancer","volume":"16","author":"Radonic","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.tranon.2026.102854_bib0024","unstructured":"FDA approves selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors | FDA. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-selpercatinib-locally-advanced-or-metastatic-ret-fusion-positive-solid-tumors."},{"key":"10.1016\/j.tranon.2026.102854_bib0025","unstructured":"FDA approves pralsetinib for non-small cell lung cancer with RET gene fusions | FDA. FDA approval on pralsetinib https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-pralsetinib-non-small-cell-lung-cancer-ret-gene-fusions."},{"key":"10.1016\/j.tranon.2026.102854_bib0026","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1200\/JCO.22.00393","article-title":"Selpercatinib in patients with RET fusion-positive non-small-cell lung cancer: updated safety and efficacy from the registrational LIBRETTO-001 phase I\/II trial","volume":"41","author":"Drilon","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2026.102854_bib0027","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S1470-2045(21)00247-3","article-title":"Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1\/2 study","volume":"22","author":"Gainor","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.tranon.2026.102854_bib0028","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1056\/NEJMoa2005653","article-title":"Efficacy of selpercatinib in RET fusion\u2013positive non\u2013small-cell lung cancer","volume":"383","author":"Drilon","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tranon.2026.102854_bib0029","doi-asserted-by":"crossref","first-page":"497","DOI":"10.6004\/jnccn.2022.0025","article-title":"Non\u2013small cell lung cancer, version 3.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Ettinger","year":"2022","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.tranon.2026.102854_bib0030","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"Oncogene-addicted metastatic non-small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up\u2606","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.tranon.2026.102854_bib0031","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2019.01521","article-title":"Implementation of novel molecular biomarkers for non-small cell lung cancer in the Netherlands: how to deal with increasing complexity","volume":"9","author":"van den Broek","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.tranon.2026.102854_bib0032","unstructured":"Behandeling pati\u00ebnten met een zeldzame mutatie bij NSCLC - richtlijn - richtlijnendatabase. https:\/\/richtlijnendatabase.nl\/richtlijn\/niet_kleincellig_longcarcinoom\/systemische_behandeling_stadium_iv_nsclc\/behandeling_pati_nten_met_een_zeldzame_mutatie_bij_nsclc.html."},{"key":"10.1016\/j.tranon.2026.102854_bib0033","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.lungcan.2022.04.001","article-title":"Mutation-tailored treatment selection in non-small cell lung cancer patients in daily clinical practice","volume":"167","author":"Steeghs","year":"2022","journal-title":"Lung Cancer"},{"key":"10.1016\/j.tranon.2026.102854_bib0034","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.lungcan.2020.10.012","article-title":"Biomarker testing in non-small cell lung cancer in routine care: analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP registry (AIO-TRK-0315)","volume":"152","author":"Griesinger","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.tranon.2026.102854_bib0035","series-title":"Epidemiology Kept Simple: an Introduction to Traditional and Modern Epidemiology","author":"Burt Gerstman","year":"2013"},{"key":"10.1016\/j.tranon.2026.102854_bib0036","series-title":"Fundamentals of Biostatistics","author":"Rosner","year":"2011"},{"key":"10.1016\/j.tranon.2026.102854_bib0037","doi-asserted-by":"crossref","DOI":"10.3390\/cells12081135","article-title":"Gene fusion detection in NSCLC routine clinical practice: targeted-NGS or FISH?","volume":"12","author":"Pecciarini","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.tranon.2026.102854_bib0038","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s00428-012-1281-4","article-title":"EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations","volume":"461","author":"Thunnissen","year":"2012","journal-title":"Virchows Arch."},{"key":"10.1016\/j.tranon.2026.102854_bib0039","doi-asserted-by":"crossref","first-page":"321","DOI":"10.5858\/arpa.2017-0388-CP","volume":"142","author":"Lindeman","year":"2018","journal-title":"Arch. Pathol. Lab. Med."},{"key":"10.1016\/j.tranon.2026.102854_bib0040","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/gcc.22229","article-title":"An evaluation and recommendation of the optimal methodologies to detect RET gene rearrangements in papillary thyroid carcinoma","volume":"54","author":"Zhang","year":"2015","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.tranon.2026.102854_bib0041","doi-asserted-by":"crossref","first-page":"351","DOI":"10.5858\/arpa.2020-0376-OA","article-title":"Analytical accuracy of RET fusion detection by break-apart fluorescence in situ hybridization","volume":"146","author":"Baker","year":"2022","journal-title":"Arch. Pathol. Lab. Med."},{"key":"10.1016\/j.tranon.2026.102854_bib0042","article-title":"Cost-effectiveness of parallel versus sequential testing of genetic aberrations for stage iv non\u2013small-cell lung cancer in the Netherlands","volume":"6","author":"Wolff","year":"2022","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.tranon.2026.102854_bib0043","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1513\/pats.200809-110LC","article-title":"Current treatments for advanced stage non-small cell lung cancer","volume":"6","author":"Stinchcombe","year":"2009","journal-title":"Proc. Am. Thorac. Soc."},{"key":"10.1016\/j.tranon.2026.102854_bib0044","unstructured":"CieBOD advies - RET-fusie detectie bij niet-kleincellig longcarcinoom. https:\/\/pathologie.nl\/wp-content\/uploads\/2024\/01\/220110_CieBOD-advies-RET-fusie-detectie-definitief.pdf."},{"key":"10.1016\/j.tranon.2026.102854_bib0045","doi-asserted-by":"crossref","DOI":"10.1038\/bjc.2014.36","article-title":"RET-rearranged non-small-cell lung carcinoma: a clinicopathological and molecular analysis","volume":"110","author":"Tsuta","year":"2014","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.tranon.2026.102854_bib0046","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1758835920928634","article-title":"Current management of RET rearranged non-small cell lung cancer","volume":"12","author":"Stinchcombe","year":"2020","journal-title":"Ther. Adv. Med. Oncol."},{"issue":"3","key":"10.1016\/j.tranon.2026.102854_bib0047","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nm.2658","article-title":"RET, ROS1 and ALK fusions in lung cancer","volume":"18","author":"Takeuchi","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.tranon.2026.102854_bib0048","unstructured":"CieBOD advies \u2013 ctDNA in bloedplasma voor primaire predictieve analyse bij NSCLC. https:\/\/pathologie.nl\/wp-content\/uploads\/2024\/07\/CieBOD-advies-ctDNA-bij-NSCLC-versie-1-12062024-voor-publicatie.pdf."}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523326001919?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523326001919?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T07:40:48Z","timestamp":1789112448000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523326001919"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":48,"alternative-id":["S1936523326001919"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2026.102854","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world evidence of RET fusion prevalence and testing in patients with metastatic non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2026.102854","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102854"}}